Study of fianlimab and cemiplimab for children and young adults with certain brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (fianlimab and cemiplimab) for children and young adults whose brain tumors have returned or gotten worse. The drugs aim to help the immune system fight the tumor, and the study will check for safety and how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called high-grade glioma or posterior fossa ependymoma that has come back or grown despite treatment.
- The tumor must be visible on an MRI scan and you must be able to have surgery to remove part or all of it.
- You are in fairly good health, with a performance score of at least 50 (like being able to do daily activities with some help).
- Your organs (like liver and kidneys) are working well enough to handle the study drugs.
- You haven't had certain immune system-related conditions or treatments that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
This trial tests a new immunotherapy combination for older patients with a specific type of colorectal cancer that has not been treated before. The goal is to see if these drugs can help the immune system fight the cancer without needing surgery or standard chemotherapy.
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Hear when a new High-Grade Glioma (HGG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.